Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), today announced that
it has signed an oncology-focused collaborative study agreement with
Merck, known as MSD outside the United States and Canada, through a
subsidiary. The collaborators will use Enumeral's human approach to
interrogating the tumor microenvironment in colorectal cancer tissues
obtained directly from patients in order to identify functional cellular
responses to immuno-oncology therapies being developed by Merck.
Enumeral’s human-driven immune profiling platform may increase the
probability of finding rare immune cells associated with disease or drug
response through improved efficiency and sensitivity. Studying rare
cells obtained directly from human patients for their functional
responses can potentially lead to identification of those patients
responsive to a therapy, while elucidating the underlying cellular basis
for such a response.
“Our platform provides the opportunity to understand broadly how
immunotherapy works in humans, based on its ability to evaluate the
function of critical rare immune cells in human clinical samples,” said
Arthur H. Tinkelenberg, Ph.D., President and CEO of Enumeral. “The
ability to determine cellular functions within these samples, we
believe, has the potential to accelerate discovery and development of
immunotherapies in oncology. We are very pleased to be working with
Merck, one of the leaders in the field of antibody immunotherapy, to
tackle these important clinical problems.”
Under the terms of the agreement, Enumeral will receive R&D funding and
is eligible to receive undisclosed future milestone payments if certain
goals are achieved. Merck has exclusive rights to data related to its
proprietary compounds that are generated from the studies.
About Enumeral’s Human-driven Immune Profiling Platform
Enumeral’s human-driven immune profiling platform is enabling and
accelerating the discovery and development of novel antibody
immunotherapies, or immunomodulators. The core technology behind
Enumeral’s platform was developed at and licensed from the Massachusetts
Institute of Technology, Harvard University, Whitehead Institute for
Biomedical Research and Massachusetts General Hospital.
Enumeral performs measurements on single immune cells in order to mine
the immune system’s rich collection of cells for information that is
difficult to obtain using other methods and that may guide the
development of effective therapeutics and diagnostics. The efficiency
and sensitivity provided through our platform increases the probability
of finding rare immune cells associated with disease or drug response.
Studying rare immune cells obtained directly from human patients for
their functional responses can potentially lead to selection of
best-in-class antibody drug candidates that may have a higher likelihood
of successful development. Such knowledge generated from our platform is
being applied to better understand which drug candidates might work in
which patients, and, at what stage of disease.
About Enumeral
Enumeral is discovering and developing novel antibody immunotherapies
that help the immune system attack diseased cells. We believe we have a
unique ability to extensively interrogate the human immune
microenvironment for candidate selection and validation. We believe our
unique capabilities enable us to measure drug effects in a
patient-specific manner, providing the basis for developing
best-in-class product candidates, based on a fundamental understanding
of how immunotherapies work in each patient. We are building a pipeline
of immunomodulators for the treatment of cancer and inflammatory
diseases and leveraging the breadth of our technology through strategic
collaborations. www.enumeral.com
Forward Looking Statements Disclosure
This press release contains certain “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Such statements reflect current beliefs of Enumeral
Biomedical Holdings, Inc. (“Enumeral”) with respect to future events and
involve known and unknown risks, uncertainties, and other factors
affecting operations, market growth, services, products and licenses. No
assurances can be given regarding the achievement of future results, and
although Enumeral believes that the expectations reflected in these
forward-looking statements are based on reasonable assumptions, actual
results may differ from the assumptions underlying the statements that
have been made regarding anticipated events. More detailed information
about Enumeral and risk factors that may affect the realization of
forward-looking statements, including forward-looking statements in this
press release, is set forth in Enumeral’s filings with the Securities
and Exchange Commission. Enumeral urges investors and security holders
to read those documents free of charge at the Commission’s website at http://www.sec.gov.
Forward-looking statements speak only as to the date they are made, and
except for any obligation under the U.S. federal securities laws,
Enumeral undertakes no obligation to publicly update any forward-looking
statement as a result of new information, future events or otherwise.
Copyright Business Wire 2014